2 Soaring Stocks Wth More Upside Potential

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to Summit Therapeutics (SMMT -4.83%) and Axsome Therapeutics (AXSM -1.68%), two biotechs that have been on fire over the past few years. Still, it's not too late to invest in these drugmakers. Here's the rundown.1. Summit TherapeuticsSummit ...